[DMARDs (Focusing on iguratimod)].

Abstract

Conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) other than methotrexate (MTX: anchor csDMARDs) are effective for single use, reinforcement of MTX, biologics and induction and maintenance of biologics-free condition. Newly developed iguratimod (IGU) does not suppress immunological reaction, therefore, it is useful for single use or combination with other csDMARDs in patients with complications. IGU can be used as a first csDMARDs before MTX use during the screening for MTX. IGU might be effective for reinforcement of MTX, biologics and induction and maintenance of biologics-free condition just like other csDMARDs. IGU can be used in wide variety of situation of the treatment of rheumatoid arthritis and it is desired that after the all-case surveillance condition for approval, IGU become a standard csDMARDs all over the world which was made in Japan.

• Authors: Satoshi Ito
• Journal: Nihon rinsho. Japanese journal of clinical medicine (Nihon Rinsho) Vol. 74 Issue 6 Pg. 948-54 (Jun 2016) ISSN: 0047-1852 [Print] Japan
• PMID: 27311184 (Publication Type: Journal Article, Review)

Chemical References

• Antirheumatic Agents
• Chromones
• Drugs, Generic
• Ribonucleosides
• Sulfonamides
• Sulfasalazine
• iguratimod
• mizoribine
• Cysteine
• bucillamine
• Tacrolimus

Topics

• Antirheumatic Agents (administration & dosage, adverse effects, therapeutic use)
• Arthritis, Rheumatoid (drug therapy)
• Chromones (administration & dosage, adverse effects, therapeutic use)
• Cysteine (adverse effects, analogs & derivatives, therapeutic use)
• Drug Discovery
• Drug Interactions
• Drug Substitution
• Drug Therapy, Combination
• Drugs, Generic
• Female
• Humans
• Male
• Ribonucleosides (adverse effects, therapeutic use)
• Sulfasalazine (adverse effects, therapeutic use)
• Sulfonamides (administration & dosage, adverse effects, therapeutic use)
• Tacrolimus (adverse effects, therapeutic use)